Drug-induced Uveitis in HIV Patients with Ocular Opportunistic Infections

References

• De Clercq E, Holy A, Rosenberg I, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986;323:464–467. doi:10.1038/323464a0.
   PubMed Web of Science ®Google Scholar
• Snoeck R, Sakuma T, De Clercq E, et al. (S)-1-[3-hydroxy- 2-(phosphonylmethoxy)propyl]cytosine, a potent and selec- tive inhibitor of human cytomegalovirus replication. Anti- microb Agents Chemother. 1988;32:1839–1844. doi:10.1128/AAC.32.12.1839
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 1):S5–14. doi:10.1086/313843.
   PubMed Web of Science ®Google Scholar
• Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol. 1996;114(7):821–827. doi:10.1001/archopht.1996.01100140035004.
   PubMed Web of Science ®Google Scholar
• Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623–683.
   PubMedGoogle Scholar
• Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166:1223–1227.
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115(5):575–582.
   PubMed Web of Science ®Google Scholar
• Ford N, Shubber Z, Saranchuk P, et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin Infect Dis. Nov2013;57(9):1351–1361.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol. 2010;4:285–299.
   PubMedGoogle Scholar
• Jabs DA. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome–bench to bedside: LXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2011 Feb;151(2):198–216.e1. doi:10.1016/j.ajo.2010.10.018.
   PubMed Web of Science ®Google Scholar
• Masur H, Whitcup SM, Cartwright C, et al. Advances in the management of AIDS-related cytomegalovirus retinitis. Ann Intern Med. 1996;12(5):126–136. doi:10.7326/0003-4819-125-2-199607150-00009.
   Google Scholar
• Kirsch LS, Arevalo JF, De Clercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired Immunodeficiency syndrome. Am J Ophthalmol. 1995;119:466–476.
   PubMed Web of Science ®Google Scholar
• Rahhal FM, Arevalo JF, Chavez de la Paz E, et al. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report. Ann Intern Med. 1996;125:98–103. doi:10.7326/0003-4819-125-2-199607150-00003.
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized controlled trial. Ann Intern Med. 1997;126:257–263. doi:10.7326/0003-4819-126-4-199702150-00001.
   PubMed Web of Science ®Google Scholar
• Bronson JJ, Ghazzouli I, Hitchcock MJM, et al. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2- phosphonylmethoxy) propyl]cytosine. J Med Chem. 1989;32:1457–1463.
   PubMed Web of Science ®Google Scholar
• Hitchcock MJ, Woods KL, Bronson JJ, et al. Intracellular metabolism of the anti-herpes agent, (S)-1-[3-hydroxy-2-(phosphonyl- methoxy) propyl]cytosine (HPMPC). Mol Pharmacol. 1992;41:197–202.
   PubMed Web of Science ®Google Scholar
• Snoeck R, Sakuma R, De Clercq E, et al. (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine, a potent and selective in- hibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988;32:1839–1844. doi:10.1128/AAC.32.12.1839.
   PubMed Web of Science ®Google Scholar
• Soike K, Huang J-L, Zhang JY, et al. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine (HPMPC) on Simian Varicella infection in mon- keys. Antiviral Res. 1991;16:17–28. doi:10.1016/0166-3542(91)90055-V.
   PubMed Web of Science ®Google Scholar
• Li SB, Yang ZH, Feng JS, et al. Activity of (S)-1-[3-hydroxy-2- (phosphonylmethoxy) propyl]cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 1990;13:237–252. doi:10.1016/0166-3542(90)90069-J.
   PubMed Web of Science ®Google Scholar
• Chavez-de la Paz E, Arevalo JF, Kirsch LS, et al. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. Ophthalmology. 1997 Mar; 104(3):539–544. Erratum in: Ophthalmology 1997 Jul;104(7):1063. doi:10.1016/S0161-6420(97)30278-4.
   PubMed Web of Science ®Google Scholar
• Kirsch LS, Arevalo JF, Chavez de la Paz E, Munguia D, de Clercq E, Freeman WR. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology. 1995Apr;102(4):533–542. discussion 542-3. Erratum in: Ophthalmology 1995 May;102(5):702. doi:10.1016/S0161-6420(95)30985-2
   PubMed Web of Science ®Google Scholar
• Taskintuna I, Rahhal FM, Arevalo JF, et al. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology. Jun 1997;104(6):1049–1057. doi:10.1016/S0161-6420(97)30188-2.
   PubMed Web of Science ®Google Scholar
• Banker AS, Arevalo JF, Munguia D, et al. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol. Aug 1997;124(2):168–180. doi:10.1016/S0002-9394(14)70781-0.
   PubMed Web of Science ®Google Scholar
• Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypo- tony after treatment with intravenous cidofovir for cytome- galovirus retinitis. Arch Ophthalmol. 1997;115:733–737. doi:10.1001/archopht.1997.01100150735008.
   PubMed Web of Science ®Google Scholar
• Akler ME, Johnson DW, Burman WJ, et al. Anterior uveitis and hypopyon after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105:651–657. doi:10.1016/S0161-6420(98)94019-2.
   PubMed Web of Science ®Google Scholar
• Ambati J, Wynne KB, Angerame MC, Robinson MR. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol. 1999;83(10):1153–1158. doi:10.1136/bjo.83.10.1153.
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr. Uveitis in HIV positive patients. Br J Ophthalmol. 2000;84(3):233–235. doi:10.1136/bjo.84.3.233.
   PubMed Web of Science ®Google Scholar
• Urban B, Bakunowicz-Łazarczyk A, Michalczuk M. Immune recovery uveitis: pathogenesis, clinical symptoms, and treatment. Mediators Inflamm. 2014;2014:971417. doi:10.1155/2014/971417.
   PubMed Web of Science ®Google Scholar
• Yeo TH, Yeo TK, Wong EP, Agrawal R, Teoh SC. Immune recovery uveitis in HIV patients with cytomegalovirus retinitis in the era of HAART therapy-a 5-year study from Singapore. J Ophthalmic Inflamm Infect. 2016 Dec;6(1):41. doi:10.1186/s12348-016-0110-3.
   PubMedGoogle Scholar
• Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci. 1998 Aug;44(2):97–106. doi:10.1093/toxsci/44.2.97.
   PubMed Web of Science ®Google Scholar
• Arevalo J, Munguia D, Faber D, et al. Correlation between intraocular pressure and CD4+ T-lymphocyte counts in patients with human immunodeficiency virus with and without cytomegalovirus retinitis. Am J Ophthalmol. 1996;122:91–96. doi:10.1016/S0002-9394(14)71968-3.
   PubMed Web of Science ®Google Scholar
• Accorinti M, Ciapparoni V, Pirraglia MP, Pivetti-Pezzi P. Treatment of severe ocular hypotony in AIDS patients with cytomegalovirus retinitis and cidofovir-associated uveitis. Ocul Immunol Inflamm 2001 9;Sep(3):211–217. doi:10.1076/ocii.9.3.211.3968.
   Google Scholar
• Winchester LC, Podany AT, Baldwin JS, Robbins BL, Fletcher CV. Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS. J Pharm Biomed Anal. 2015;104:55–61. doi:10.1016/j.jpba.2014.11.011.
   PubMed Web of Science ®Google Scholar
• Havlir D, Torriani F, Dub E M. Uveitis associated with rifabutin prophylaxis. Ann Intern Med. 1194;121(7):510–512. doi:10.7326/0003-4819-121-7-199410010-00006.
   PubMed Web of Science ®Google Scholar
• Fuller JD, Stanfield LE, Craven DE. Rifabutin prophylaxis and uveitis. N Engl J Med. 1994;330:1315–1316. doi:10.1056/NEJM199405053301816.
   PubMed Web of Science ®Google Scholar
• Shafran SD, Descheˆnes J, Miller M, et al. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. N Engl J Med. 1994;330(6):438–439. doi:10.1056/NEJM199402103300616.
   PubMed Web of Science ®Google Scholar
• Siegal FP, Eilbott D, Burger H, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS. 1990;4(5):433–441. doi:10.1097/00002030-199005000-00009.
   PubMed Web of Science ®Google Scholar
• Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. Sep 16 1993;329(12):828–833. doi:10.1056/NEJM199309163291202.
   PubMed Web of Science ®Google Scholar
• Saran BR, Maguire AM, Nichols C, et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Myco- bacterium avium complex infection with rifabutin. Arch Ophthalmol. 1994;112:1159–1165. doi:10.1001/archopht.1994.01090210043015.
   PubMed Web of Science ®Google Scholar
• DATRI 001 Study Group. Coadministration of clarithromycin (CL) alters the concentration-time profile of rifabutin (RFB) [abstract]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994:3
   Google Scholar
• Trapnell CB, Narang PK, Li R, Lewis R, Colborn D, Lavelle J. Fluconazole (FLU) increases rifabutin (RIF) absorption in HIV(/) patients on stable zidovudine (ZDV) therapy [abstract]. In: Program and abstracts: IX International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation, 1993:504
   Google Scholar
• Narang PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Bianchine JR. Fluconazole and enhanced effect of rifabutin prophylaxis [letter]. N Engl J Med. 1994;330:1316. doi:10.1056/NEJM199405053301817.
   PubMed Web of Science ®Google Scholar
• Shafran SD, Singer J, Zarowny DP, et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis. 1998;177(1):252–255. doi:10.1086/517366.
   PubMed Web of Science ®Google Scholar
• Skolik S, Willermain F, Caspers LE. Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. Ocul Immunol Inflamm. 2005 Dec;13(6):483–485. PubMed PMID: 16321897. doi:10.1080/09273940590951115.
   PubMed Web of Science ®Google Scholar
• Smith WM, Reddy MG, Hutcheson KA, et al. Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect. 2012;2(3):149–152. doi:10.1007/s12348-012-0059-9.
   PubMedGoogle Scholar
• Chaknis MJ, Brooks SE, Mitchell KT, Marcus DM. Inflammatory opacities of the vitreous in rifabutin-associated uveitis. Am J Ophthalmol. 1996;122(4):580–582. doi:10.1016/S0002-9394(14)72124-5.
   PubMed Web of Science ®Google Scholar
• Trone MC, Manoli P, Mattei J, Thuret G, Gain P, Stephan JL. Rifabutin-associated uveitis in a 10-year-old child with HIV: case report and review of the literature. J Fr Ophtalmol. Oct 2018;41(8):e391–e393.
   PubMed Web of Science ®Google Scholar
• Dunn AM, Tizer K, Cervia JS. Rifabutin-associated uveitis in a pediatric patient. Pediatr Infect Dis J. 1995;14:246–247.
   PubMed Web of Science ®Google Scholar
• Le Saux N, MacDonald N, Dayneka N. Rifabutin ocular toxic- ity mimicking endophthalmitis. Pediatr Infect Dis J. 1997;16:716–718.
   PubMed Web of Science ®Google Scholar
• Smith JA, Mueller BU, Nussenblatt RB, Whitcup SM. Corneal endothelial deposits in children positive for human immunode- ficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol. 1999;127:164–169.
   PubMed Web of Science ®Google Scholar
• Worlledge S, Hong Kong Treatment Services-Royal Postgraduate Medical 33. School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. The detection of rifampicin- dependent antibodies. Scand J Respir Dis. 1973;84(S):60–63.
   Google Scholar
• Nichols CW. Mycobacterium avium complex infection, rifabutin, and uveitis - is there a connection? Clin Infect Dis. 1996 Apr;22(Suppl 1):S43–7. discussion S47-9. Review.
   PubMedGoogle Scholar
• Kemper CA, Havlir D, Bartok AE, et al. Transient bacteremia due to Mycobacterium avium complex in patients with AIDS. J Infect Dis. 1994;170:488–493.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997;277:145–153.
   PubMed Web of Science ®Google Scholar
• Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother. 2007;8:957–964.
   PubMed Web of Science ®Google Scholar
• Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med. 1997;336:138–140.
   PubMed Web of Science ®Google Scholar
• Lacy MK, Abriola KP. Indinavir: a pharmacologic and clinical review of a new HIV protease inhibitor. Conn Med. 1996;60(12):723–727.
   PubMedGoogle Scholar
• Gariano RF, Cooney EL. Uveitis following administration of the protease inhibitor indinavir to a patient with AIDS. Clin Infect Dis. 1997;24:529.
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.
   PubMed Web of Science ®Google Scholar
• Wohl D, Oka S, Clumeck N, et al. A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defi c Syndr. 2016;72:58–64.
   PubMed Web of Science ®Google Scholar
• Unger NR, Worley MV, Kisgen JJ, Sherman EM, Childs-Kean LM. Elvitegravir for the treatment of HIV. Expert Opin Pharmacother. 2016;17:2359–2370.
   PubMed Web of Science ®Google Scholar
• Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016;3(12):561–568.
   PubMed Web of Science ®Google Scholar